Voyager's Losses Mount Amid Plummeting Collaboration Revenue

TL;DR

**Voyager's cash burn is accelerating, and with collaboration revenue drying up, this stock is a risky bet unless they land a major new deal ASAP.**

AI Summary

Voyager Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $92.295 million, a substantial rise from $30.515 million in the same period of 2024. Collaboration revenue decreased sharply to $25.038 million for the nine months ended September 30, 2025, down from $73.723 million in the prior year, indicating a significant reduction in funding from partners. Research and development expenses increased to $98.722 million for the nine months ended September 30, 2025, up from $91.785 million in 2024, reflecting continued investment in its pipeline. The company's cash, cash equivalents, and marketable securities stood at $229.0 million as of September 30, 2025, which is expected to fund operations for at least the next twelve months. Total assets decreased from $393.050 million at December 31, 2024, to $288.311 million at September 30, 2025. The accumulated deficit grew to $418.5 million as of September 30, 2025, highlighting a history of operating losses and no product revenue. The company continues to advance its TRACER AAV capsid discovery platform and a non-viral therapeutics platform for neurological diseases.

Why It Matters

Voyager's substantial increase in net loss and sharp decline in collaboration revenue signal a challenging financial outlook, potentially impacting its ability to fund critical R&D for neurological disease treatments. For investors, this raises concerns about long-term viability and dilution risk, especially given the reliance on equity financing and lack of product revenue. Employees might face job insecurity if financial pressures intensify, while customers (future patients) could see delays in promising gene therapies. In the competitive biotech landscape, reduced funding could hinder Voyager's ability to compete with larger players like Alexion and Novartis, who are also its partners, potentially slowing innovation in the gene therapy space.

Risk Assessment

Risk Level: high — Voyager's net loss for the nine months ended September 30, 2025, surged to $92.295 million from $30.515 million in the prior year, representing a 202% increase. Collaboration revenue plummeted by 66% from $73.723 million in 2024 to $25.038 million in 2025, indicating a significant reduction in external funding. The accumulated deficit of $418.5 million as of September 30, 2025, coupled with no product revenue, highlights a precarious financial position reliant on future financing or collaboration payments.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to VYGR given the accelerating losses and significant drop in collaboration revenue. Monitor closely for any new strategic partnerships or substantial financing rounds, as these are critical for the company's short-term survival and long-term pipeline development. Without new funding, further dilution or operational scaling back is highly probable.

Financial Highlights

debt To Equity

0.31

revenue

$25,038,000

operating Margin

-407.7%

total Assets

$288,311,000

total Debt

$68,486,000

net Income

-$92,295,000

eps

-$0.47

gross Margin

N/A

cash Position

$229,000,000

revenue Growth

-66.0%

Revenue Breakdown

Key Numbers

• $92.295M — Net Loss (9 months ended Sep 30, 2025) (Increased from $30.515M in 2024, a 202% increase, indicating accelerating losses.)
• $25.038M — Collaboration Revenue (9 months ended Sep 30, 2025) (Decreased from $73.723M in 2024, a 66% drop, signaling reduced partner funding.)
• $98.722M — Research and Development Expenses (9 months ended Sep 30, 2025) (Increased from $91.785M in 2024, reflecting continued investment in pipeline.)
• $418.5M — Accumulated Deficit (as of Sep 30, 2025) (Highlights a history of significant operating losses and no product revenue.)
• $229.0M — Cash, Cash Equivalents, and Marketable Securities (as of Sep 30, 2025) (Expected to fund operations for at least 12 months, but significantly lower than previous periods.)
• $288.311M — Total Assets (as of Sep 30, 2025) (Decreased from $393.050M at December 31, 2024, indicating asset reduction.)
• $0.47 — Net Loss Per Share (3 months ended Sep 30, 2025) (Increased from $0.16 in 2024, reflecting higher losses per share.)
• 55,600,084 — Outstanding Shares (as of Nov 3, 2025) (Indicates potential for further dilution if more capital is needed.)

Key Players & Entities

• Voyager Therapeutics, Inc. (company) — biotechnology company
• Neurocrine Biosciences, Inc. (company) — collaboration partner
• Novartis Pharma AG (company) — collaboration partner
• Alexion, AstraZeneca Rare Disease (company) — licensee
• Pfizer Inc. (company) — former licensee
• TRACER (other) — AAV capsid discovery platform
• Nasdaq Global Select Market (other) — stock exchange
• SEC (regulator) — Securities and Exchange Commission
• Delaware (other) — state of incorporation
• Lexington, Massachusetts (other) — principal executive offices location

FAQ

Risk Factors

• Accelerating Net Losses and Growing Accumulated Deficit [high — financial]: The company reported a net loss of $92.295 million for the nine months ended September 30, 2025, a 202% increase from $30.515 million in the same period of 2024. The accumulated deficit grew to $418.5 million as of September 30, 2025, indicating a history of significant operating losses and no product revenue.
• Decreasing Cash Position and Dependence on Future Funding [high — financial]: Cash, cash equivalents, and marketable securities stood at $229.0 million as of September 30, 2025. While this is expected to fund operations for at least twelve months, it represents a decrease from previous periods and the company's substantial net losses and accumulated deficit suggest a continued need for external financing.
• Sharp Decline in Collaboration Revenue [high — financial]: Collaboration revenue decreased by 66% to $25.038 million for the nine months ended September 30, 2025, down from $73.723 million in the prior year. This significant drop signals reduced funding from partners, impacting the company's revenue streams.
• Increased Research and Development Expenses [medium — operational]: Research and development expenses increased to $98.722 million for the nine months ended September 30, 2025, up from $91.785 million in 2024. While this reflects continued investment in its pipeline, it contributes to the growing net loss.
• Reduction in Total Assets [medium — financial]: Total assets decreased from $393.050 million at December 31, 2024, to $288.311 million at September 30, 2025. This reduction in asset base may indicate a scaling back of operations or asset disposals.
• Potential for Shareholder Dilution [medium — financial]: With 55,600,084 outstanding shares as of November 3, 2025, and a significant accumulated deficit, the company may need to issue additional shares to raise capital, potentially diluting existing shareholders' ownership.
• Dependence on Regulatory Approvals for Pipeline Advancement [high — regulatory]: As a biotechnology company, Voyager's success is heavily dependent on the successful development and regulatory approval of its therapeutic candidates. Delays or failures in clinical trials or the regulatory review process can significantly impact the company's prospects.
• Competitive Landscape in Neurological Diseases [medium — market]: The company operates in the highly competitive field of developing treatments for neurological diseases. Numerous other companies are also pursuing similar targets, which could lead to pricing pressures and market share challenges.

Industry Context

Voyager Therapeutics operates in the highly competitive biotechnology sector, specifically focusing on gene therapies for neurological diseases. The industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Companies in this space often rely on strategic partnerships and collaborations for funding and expertise, facing challenges in translating scientific innovation into commercially viable products.

Regulatory Implications

As a clinical-stage biotechnology company, Voyager is subject to stringent regulatory oversight from bodies like the FDA. The success of its pipeline hinges on navigating complex clinical trial processes and obtaining regulatory approvals. Any delays, setbacks in trials, or adverse regulatory decisions pose significant risks to the company's future.

What Investors Should Do

1. Monitor cash burn rate and runway closely.
2. Evaluate the impact of reduced collaboration revenue.
3. Assess the progress and potential of the R&D pipeline.
4. Consider the risk of future dilution.

Key Dates

• 2025-09-30: Quarterly Financial Reporting (10-Q) — Revealed a significant increase in net loss and a sharp decrease in collaboration revenue, highlighting financial challenges.
• 2024-09-30: Prior Year Comparable Period — Provides a baseline for comparison, showing a substantial deterioration in financial performance for the nine months ended September 30, 2025.
• 2024-12-31: End of Previous Fiscal Year — Marks the starting point for asset comparison, showing a decrease in total assets by September 30, 2025.
• 2025-11-03: Outstanding Shares Reported — Indicates the current share count, relevant for assessing potential dilution if further capital is raised.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (Voyager's accumulated deficit of $418.5 million highlights its history of operating losses and lack of product revenue.)

Collaboration Revenue

Revenue generated from agreements with other companies, often involving joint development or licensing of technology or products. (A significant decrease in collaboration revenue for Voyager indicates reduced funding from partners.)

Marketable Securities

Investments in financial instruments that can be easily bought or sold on public exchanges, such as stocks and bonds. (Marketable securities are a significant component of Voyager's current and non-current assets, contributing to its overall cash position.)

Deferred Revenue

Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. (The decrease in deferred revenue suggests that previously recognized revenue from partner agreements has been earned or expired.)

Operating Lease, Right-of-Use Assets

An asset representing the right to use a leased asset over the lease term, recognized under accounting standards for leases. (These assets represent Voyager's long-term commitments for leased properties or equipment.)

TRACER AAV capsid discovery platform

A proprietary technology platform used by Voyager Therapeutics to discover and engineer adeno-associated virus (AAV) capsids for gene therapy delivery. (This platform is central to Voyager's research and development efforts for neurological diseases.)

Year-Over-Year Comparison

Voyager Therapeutics has experienced a significant financial downturn compared to the prior year. For the nine months ended September 30, 2025, net loss more than tripled to $92.295 million, driven by a 66% decrease in collaboration revenue to $25.038 million. While R&D expenses saw a modest increase to $98.722 million, the overall financial health has deteriorated, evidenced by a decrease in total assets and a growing accumulated deficit. New risks related to the sharp decline in partner funding and the potential for dilution are now more pronounced.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select

Filing Documents

• vygr-20250930x10q.htm (10-Q) — 1701KB
• vygr-20250930xex31d1.htm (EX-31.1) — 13KB
• vygr-20250930xex31d2.htm (EX-31.2) — 13KB
• vygr-20250930xex32d1.htm (EX-32.1) — 10KB
• vygr-20250930x10q006.jpg (GRAPHIC) — 76KB
• 0001104659-25-108846.txt ( ) — 7190KB
• vygr-20250930.xsd (EX-101.SCH) — 43KB
• vygr-20250930_cal.xml (EX-101.CAL) — 53KB
• vygr-20250930_def.xml (EX-101.DEF) — 170KB
• vygr-20250930_lab.xml (EX-101.LAB) — 390KB
• vygr-20250930_pre.xml (EX-101.PRE) — 284KB
• vygr-20250930x10q_htm.xml (XML) — 1293KB

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "contemplate," "anticipate," "goals," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our plans to develop and commercialize our proprietary adeno-associated virus, or AAV, gene therapy, antibody, and non-viral therapeutic product candidates; our ability to continue to develop our proprietary gene therapy platform technologies, including our TRACER TM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) discovery platform, our vectorized antibody platform, our non-viral therapeutics platform, and our proprietary antibody, gene therapy, vectorized antibody, and non-viral therapeutic programs; our ability to identify and optimize product candidates , proprietary AAV capsids , and non-viral blood-brain-barrier shuttles ; our strategic collaborations and licensing agreements with, and funding from, our collaboration partners

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 5 CONDENSED CONSOLIDATED BALANCE SHEETS 5 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 6 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 7 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 8 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 9 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 20 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 36

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 36 ITEM 1A.

RISK FACTORS

RISK FACTORS 37 ITEM 5. OTHER INFORMATION 37 ITEM 6. EXHIBITS 38

SIGNATURES

SIGNATURES 39 4 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Voyager Therapeutics, Inc. Condensed Consolidated Balance Sheet s (amounts in thousands, except share and per share data) (unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 45,125 $ 71,367 Marketable securities 163,805 195,317 Accounts receivable 3,186 1,504 Related party collaboration receivable (see note 8) 851 676 Prepaid expenses and other current assets 6,618 7,945 Total current assets 219,585 276,809 Property and equipment, net 13,291 14,314 Restricted cash 5,614 2,874 Marketable securities 20,081 65,704 Operating lease, right-of-use assets 29,740 33,349 Total assets $ 288,311 $ 393,050 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,116 $ 3,996 Accrued expenses 14,953 14,171 Operating lease liabilities 7,848 7,227 Deferred revenue (see note 8) 10,578 24,394 Total current liabilities 35,495 49,788 Operating lease liabilities, net of current portion 30,520 36,499 Deferred revenue, net of current portion 1,471 6,003 Other non-current liabilities 1,000 1,000 Total liabilities 68,486 93,290 Commitments and contingencies (see note 7) Stockholders' equity: Preferred stock, $ 0.001 par value: 5,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value: 120,000,000 shares authorized at September 30, 2025 and December 31, 2024; 55,482,262 and 54,731,316 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 56 55 Additional paid-in capital 638,241 626,296 Accumulated other comprehensive income (loss) 7 ( 407 ) Accumulated deficit ( 418,479 ) ( 326,184 ) Total stockholders' equity 219,825 299,760 Total liabilities and stockholders' equity $ 288,3

View Full Filing

View this 10-Q filing on SEC EDGAR